Clinical trials in Oldenburg In Holstein – page 9

212 clinical trials in Oldenburg In Holstein, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Oldenburg In Holstein at a glance

212

clinical trials

Research sites1

Quick filters

212 trials in Oldenburg In Holstein

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Taletrectinib
Sponsor:Nuvation Bio Inc.

Contact Research Centre

Systemic candida

Not yet recruiting

Shortening treatment duration in adults with uncomplicated candidemia: caspofungin acetate versus saline and sodium lactate placebo

Registered drug

Shortening treatment duration in adults with uncomplicated candidemia: caspofungin acetate versus saline and sodium lactate placebo

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Caspofungin Acetate
Sponsor:University Of Cologne

Contact Research Centre

K-ras gene mutation+2

Not yet recruiting

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:GPOH gGmbH

Contact Research Centre

Type 2 diabetes mellitus

Not yet recruiting

Study on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes

Registered drugNo placebo

Study on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bromocriptine
Sponsor:Eli Lilly Cork Limited

Contact Research Centre

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Cytarabine
Sponsor:GPOH gGmbH

Contact Research Centre

Cardiovascular disorder

Not recruiting

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Psoriasis

Not recruiting

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Apremilast
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Sonelokimab
Sponsor:MoonLake Immunotherapeutics AG

Contact Research Centre

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Type 2 diabetes mellitus+2

Not recruiting

Study of Orforglipron for Weight Management in People with Obesity or Overweight, With or Without Type 2 Diabetes

Investigational

Study of Orforglipron for Weight Management in People with Obesity or Overweight, With or Without Type 2 Diabetes

Investigational

Germany

Participants:18–64 years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Oldenburg In Holstein

What the registry says about research in the country

01 Metabolic Disorders

Innovative clinical trials focusing on Type 2 Diabetes management and treatments, including studies of novel weekly insulin alternatives and oral medications for glycemic control.

Glycemic Control Studies
Insulin Alternatives Research
Cardiovascular Outcomes

Multiple studies evaluating new therapeutic approaches for better diabetes management and reducing cardiovascular risks.

02 Weight Management

Comprehensive research into obesity treatment and weight-related conditions, examining new therapeutic combinations and their effects on weight loss and associated health conditions.

Weight Loss Interventions
Obesity Medications
Comorbidity Management

Studies focusing on innovative approaches to weight management and treating obesity-related health complications.

03 Cardiovascular Health

Research examining treatments for atherosclerotic cardiovascular disease and related conditions, with emphasis on preventing major adverse cardiovascular events.

Cardiovascular Risk Reduction
Lipid Management
Preventive Therapies

Trials evaluating new medications for improving cardiovascular outcomes in high-risk patients.

04 Gastrointestinal Studies

Clinical investigations of treatments for Crohn's Disease and other digestive conditions, focusing on long-term efficacy and safety of new therapeutic approaches.

Inflammatory Bowel Disease
Long-term Treatment Outcomes
Disease Management

Studies aimed at improving quality of life for patients with chronic gastrointestinal conditions.

05 Oncology Research

Advanced studies in colorectal cancer treatment and management, including innovative approaches to Stage II and III cancer therapy.

Cancer Treatment Protocols
Disease-Free Survival
Adjuvant Therapy

Trials evaluating new treatment strategies for improving outcomes in cancer patients.

Back to Germany All countries